SCHEMBL339476

SCHEMBL339476

CCCCCCCCCCCCCCOC1CCC(OCCOP(=O)(O)OCC[N+]2(C)CCCCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.44
MAPK14 Q16539 2/20 0.39
TERT O14746 1/20 0.39
UCHL3 P15374 1/20 0.39
AKT1 P31749 1/20 0.39
LMNA P02545 2/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
LPAR3 Q9UBY5 5/20 0.36
LPAR1 Q92633 4/20 0.36
LPAR2 Q9HBW0 2/20 0.36
KDM4E B2RXH2 1/20 0.36
EPHX2 P34913 1/20 0.33
PLA2G2C Q5R387 1/20 0.33
KMT2A Q03164 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
GBA1 P04062 1/20 0.33
P2RY10 O00398 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338753 1.00 CDC25A (0.44) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14447915 0.87 CDC25A (0.48) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14448006 0.87 CDC25A (0.48) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14447789 0.87 CDC25A (0.48) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14448004 0.87 CDC25A (0.48) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14447903 0.86 CDC25A (0.56) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL4973797 0.86 CDC25A (0.56) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL4970288 0.86 CDC25A (0.56) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14447865 0.86 CDC25A (0.56) CDC25AMAPK14TERTUCHL3AKT1
SCHEMBL14447867 0.86 CDC25A (0.56) CDC25AMAPK14TERTUCHL3AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US claimed
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids MAK SCIENTIFIC CORPORATION (US) 2006-05-18 US claimed
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US disclosed
EP-1578754-A4 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS MAKSCIENTIFIC LLC (US) 2006-07-19 EP disclosed
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids MAK SCIENTIFIC CORPORATION (US) 2006-05-18 US disclosed
EP-1578754-A2 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS MakScientific Corporation (US) 2005-09-28 EP disclosed
WO-2004041167-A2 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS CALOGEROPOULOU THEODORA (GR) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids PHOSPHO1, PLTP, PLA2G2C CDC25A 957/4885MAPK14 2151/4885TERT 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.